Results 11 to 20 of about 6,678 (215)

Bronchoalveolar Lavage Fluid Metagenomic Second-Generation Sequencing Assists in Guiding the Treatment of Visceral Leishmaniasis: A Case Report [PDF]

Infection and Drug Resistance
Jian Li,1,* Li Liu,2,* Zhiyun Gao,1 Xia Chuai,3 Xiaokun Liu,4 Xiaobo Zhang,2 Xinyu Zhang,2 Xiaoqing Su,2 Qian Xu,2 Zhuojun Deng2 1Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China ...
Li J, Liu L, Gao Z, Chuai X, Liu X, Zhang X, Zhang X, Su X, Xu Q, Deng Z   +9 more
doaj   +2 more sources

Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia [PDF]

BMC Public Health, 2018
Background Cutaneous leishmaniasis causes a high disease burden in Colombia, and available treatments present systemic toxicity, low patient compliance, contraindications, and high costs.
Jaiberth Antonio Cardona-Arias, Liliana López-Carvajal, Mery Patricia Tamayo-Plata, Iván Darío Vélez   +3 more
doaj   +3 more sources

Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya [PDF]

Bulletin of the World Health Organization, 2001
OBJECTIVE: To compare the use of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis (kala-azar). METHODS: A total of 102 patients with confirmed kala-azar were treated in a mission hospital in West Pokot region ...
Moore Elinore, O?Flaherty Deidre, Heuvelmans Hans, Seaman Jill, Veeken Hans, Wit Sjoukje de, Davidson Robert N.   +6 more
doaj   +2 more sources

Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform. [PDF]

PLoS Negl Trop Dis
Background: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL endemic areas.
Singh-Phulgenda S, Kumar R, Dahal P, Munir A, Rashan S, Chhajed R, Naylor C, Maguire BJ, Siddiqui NA, Harriss E, Rahi M, Alves F, Sundar S, Stepniewska K, Musa A, Guerin PJ, Pandey K.   +16 more
europepmc   +3 more sources

Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation inLeishmania donovani-Infected Macrophages

Antimicrobial Agents and Chemotherapy, 2006
Jayati Basu, Ananda Mookerjee, Prosenjit Sen, Suniti Bhaumik, Pradip Sen, Subha Banerjee, Ksudiram Naskar, Soumitra Kumar Choudhuri, Bhaskar Saha, Sanghamitra Raha, Syamal Roy   +10 more
openalex   +2 more sources

Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine.

The Indian journal of medical research, 2007
Sodium antimony gluconate (SAG) and miltefosine used in the treatment of kala-azar are known to cause several side effects but severe thrombocytopenia has not been reported. Four cases of severe thrombocytopenia, two caused by SAG and two by miltefosine were promptly detected and treated by immediate withdrawal of the offending drugs, platelet and ...
C.P. Thakur, Ashish Kumar, Gaurab Mitra, S Thakur, Meenakshi Thakur   +4 more
openalex   +2 more sources

Leishmaniasis with secondary hemophagocytic syndrome: a case report [PDF]

Zhenduanxue lilun yu shijian, 2022
Leishmaniasis is an infection caused by Leishmania. Different species of Leishmania cause different clinical syndromes. Hemophagocytic syndrome (HPS) is an immune related systemic inflammatory response syndrome mediated by many factors.
XIONG Xinhai, LI Jia, DING Xiaosong, JI Congcong, SHI Hourong, XIANG Minjie
doaj   +1 more source

Treatment of leishmaniasis with chemotherapy and vaccine: a mathematical model

Journal of Biological Dynamics, 2023
Leishmaniasis, an infectious disease, manifests itself mostly in two forms, cutaneous leishmaniasis (CL) and, a more severe and potentially deadly form, visceral leishmaniasis (VL).
Nourridine Siewe, Avner Friedman
doaj   +1 more source

Metabolomics to unveil and understand phenotypic diversity between pathogen populations [PDF]

, 2010
Visceral leishmaniasis is caused by a parasite called Leishmania donovani, which every year infects about half a million people and claims several thousand lives. Existing treatments are now becoming less effective due to the emergence of drug resistance.
A Kamleh, A Scalbert, AK Chavali, Andris Jankevics, BO Keller, C Bern, C Christin, CC HsuChen, D Kumar, David G. Watson, DS Wishart, E Cauchetier, E Fahy, F Chappuis, F Hong, FR Opperdoes, G Barratt, Graham H. Coombs, H Ogata, HC Maltezou, HJ Atherton, HP de Koning, HW Murray, J Alvar, J Trygg, J Vandesompele, JC Mottram, Jean-Claude Dujardin, JV Olsen, K Zhang, K Zhang, Kirstyn Brunker, KW Tintaya, M Basselin, M Basselin, M Rakotomanga, MA Basinger, MA Doyle, MA Kamleh, MA Kamleh, MB Eisen, MK Wassef, MZ Alam, N Mbongo, N Van Meirvenne, R Breitling, R Breitling, R Breitling, RA Scheltema, RA Scheltema, RA Scheltema, Rainer Breitling, Richard A. Scheltema, Ruben t'Kindt, S Rijal, S Sundar, Saskia Decuypere, Suman Rijal, T Laurent, T Naderer, Timothy G. Geary, VP Shah, W Windig, WB Dunn   +63 more
core   +11 more sources

Therapeutic modalities in post kala-azar dermal leishmaniasis: A systematic review of the effectiveness and safety of the treatment options

Indian Journal of Dermatology, 2021
Post-kala-azar dermal Leishmaniasis (PKDL) is one of the important neglected tropical diseases, which has a tremendous epidemiological significance, being the reservoir of kala-azar.
Adrija Datta, Indrashis Podder, Anupam Das, Amrita Sil, Nilay Kanti Das   +4 more
doaj   +1 more source